PD-L1, PD-1 and CTLA-4 are expressed at higher levels in the low-risk score group compared with the high-risk score group, suggesting that tumor samples with the low-risk score may tend to have favorable responses to anticancer immunotherapies. This evidence concerns the gene CTLA4 and neoplasm.